“It had made its way into two Phase III trials thanks to Phase Ib data demonstrating its efficacy at reducing plaques of the peptide amyloid beta — a defining feature of Alzheimer’s disease — with observable clinical benefit to boot. But last month, Biogen and its partner, Japan’s Eisai, shocked the world by halting the Phase III studies, ENGAGE and EMERGE , after a futility analysis by the program’s independent data monitoring committee showed the trials were likely to fail.”
Read the full story at medcitynews.com
Failure of once-promising Alzheimer’s drug reinforces doubts about amyloid beta | Med City News
More from Current EventMore posts in Current Event »
- Former NFL Wife on Her Husband’s Battle with CTE
- Capito, Collins introduce bill to increase awareness of Alzheimer’s services | Ripon Advance
- ‘Young Blood’ Researchers Are Still in the Pursuit to Stall Aging, Slow Alzheimer’s | Being Patient
- ‘It is not alarmist to say that the people of Florida are being slowly poisoned by the water’ | Opinion | Miami Herald
- NYPD Blue and Deadwood Creator David Milch Reveals He Has Been Diagnosed with Alzheimer’s Disease | People